估算肾小球滤过率急性下降后停用肾素-血管紧张素系统抑制剂
该回顾性队列研究采用目标试验模拟方法,利用加拿大曼尼托巴省的电子健康记录与生命统计联动数据,纳入2008年1月1日至2021年12月31日新处方肾素-血管紧张素系统抑制剂、并在90天内估算肾小球滤过率下降超过15%的成人。经倾向评分匹配后共4233例,其中1411例(33.3%)停药、2822例(66.6%)继续用药。停药组较继续用药组死亡风险更高(HR 1.23;95%CI 1.07-1.41),终末期肾病风险更高(HR 1.74;95%CI 1.28-2.38),主要不良心血管事件(HR 1.13;95%CI 0.99-1.28)与急性肾损伤(HR 1.11;95%CI 0.90-1.37)风险未显著升高。作者认为,这些发现提示需要进一步研究以了解频繁停药的原因,并制定改善持续用药的策略。
要点
- 新处方肾素-血管紧张素系统抑制剂后90天内估算肾小球滤过率下降超过15%的成人中,33.3%(1411/4233)停药、66.6%(2822/4233)继续用药。
- 与继续用药相比,停药者死亡风险更高(HR 1.23;95%CI 1.07-1.41),终末期肾病风险更高(HR 1.74;95%CI 1.28-2.38)。
- 停药者主要不良心血管事件风险(HR 1.13;95%CI 0.99-1.28)与急性肾损伤风险(HR 1.11;95%CI 0.90-1.37)较继续用药者未显著升高。
- 作者认为,需进一步研究以了解肾素-血管紧张素系统抑制剂频繁停药的原因,并制定策略改善其持续使用。
适用人群与场景
- 加拿大曼尼托巴省成人(年龄≥18岁),在2008年1月1日至2021年12月31日期间新获得肾素-血管紧张素系统抑制剂处方,且处方后90天内估算肾小球滤过率下降超过15%。
- 研究基于曼尼托巴省健康政策中心的电子健康记录并与该省生命统计联动,采用目标试验模拟与倾向评分匹配。
诊断标准与关键阈值
- 暴露定义:在估算肾小球滤过率下降15%发生后90天内是否续取肾素-血管紧张素系统抑制剂处方,未续取定义为停药,续取定义为继续用药。
- 结局在180天后评估:主要结局为终末期肾病或死亡,次要结局为主要不良心血管事件(包括心肌梗死、心力衰竭、卒中或心血管死亡)或急性肾损伤。
研究设计与关键结果
- 研究类型:采用目标试验模拟方法的回顾性队列研究,数据为加拿大曼尼托巴省电子健康记录与生命统计联动数据。
- 共纳入4233例(平均[SD]年龄64.6[16.2]岁;2697例男性[51.1%])启用肾素-血管紧张素系统抑制剂后估算肾小球滤过率下降超过15%的患者;1411例(33.3%)停药,2822例(66.6%)继续用药。
- 与继续用药组相比,停药组死亡风险更高(HR 1.23;95%CI 1.07-1.41),终末期肾病风险更高(HR 1.74;95%CI 1.28-2.38)。
- 停药组主要不良心血管事件风险(HR 1.13;95%CI 0.99-1.28)与急性肾损伤风险(HR 1.11;95%CI 0.90-1.37)较继续用药组未显著升高。
- 分析采用Cox比例风险模型,按意向性治疗方式比较暴露与结局。
- 数据分析时间为2024年1月14日至2026年1月22日。
证据类型、等级与局限
- 证据类型:回顾性队列研究,采用目标试验模拟与倾向评分匹配。
- 作者结论:启用肾素-血管紧张素系统抑制剂后估算肾小球滤过率急性下降者中,停药与继续用药相比与终末期肾病和死亡相关。
- 作者认为需进一步研究以了解肾素-血管紧张素系统抑制剂频繁停药的原因,并制定策略改善其持续使用。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对启用肾素-血管紧张素系统抑制剂后90天内估算肾小球滤过率下降超过15%的成人,本研究结果提示停药与死亡和终末期肾病风险升高相关,继续用药者上述风险较低。
- 作者认为需进一步研究以了解该情形下频繁停药的原因,并制定策略改善肾素-血管紧张素系统抑制剂的持续使用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Although renin-angiotensin system inhibitors (RASIs) slow the progression of chronic kidney disease, these agents are frequently discontinued if acute declines in the estimated glomerular filtration rate (eGFR) occur after their initiation.
OBJECTIVE: To examine the risk for cardiovascular, kidney, and mortality outcomes associated with discontinuation vs continuation of RASIs in patients with an acute decline in eGFR after RASI initiation.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study using a target trial emulation approach leveraged electronic health record data from the Manitoba Centre for Health Policy that were linked to vital statistics in the province of Manitoba, Canada. Propensity score matching was applied to identify adults (aged ≥18 years) receiving new prescriptions for RASIs between January 1, 2008, and December 31, 2021, who subsequently had an eGFR decline of more than 15% within 90 days of the prescription. Data were analyzed between January 14, 2024, and January 22, 2026.
EXPOSURE: RASI discontinuation (vs continuation) defined based on whether a RASI prescription was refilled within 90 days after a decline in eGFR of 15% had occurred.
MAIN OUTCOMES AND MEASURES: The primary outcomes of end-stage kidney disease (ESKD) or death, and secondary outcomes of major adverse cardiovascular events (MACEs) (including myocardial infarction, heart failure, stroke, or cardiovascular mortality) or acute kidney injury (AKI) were examined after 180 days. Cox proportional hazards models were used to compare the exposure with the outcomes in an intention-to-treat approach.
RESULTS: A total of 4233 patients (mean [SD] age, 64.6 [16.2] years; 2697 male [51.1%]) who had a more than 15% decline in eGFR after starting a RASI were included; 1411 patients (33.3%) discontinued RASIs, and 2822 (66.6%) continued RASIs . Patients who discontinued vs continued RASIs had a higher risk of death (hazard ratio [HR], 1.23; 95% CI, 1.07-1.41) and ESKD (HR, 1.74; 95% CI, 1.28-2.38). Their risk of MACEs (HR, 1.13; 95% CI, 0.99-1.28) and AKI (HR, 1.11; 95% CI, 0.90-1.37) was not significantly higher.
CONCLUSIONS AND RELEVANCE: This cohort study found that discontinuation of RASIs after an acute decline in eGFR was associated with ESKD and death compared with continuing RASIs. These findings suggest that further study is needed to understand reasons for frequent discontinuation of RASIs and devise strategies to improve their persistent use.
参考来源
- Ku E, Tangri N, Brar R, et al. Discontinuation of RAS Inhibition After an Acute Decline in Estimated Glomerular Filtration Rate. JAMA Netw Open. 2026. PMID: 41893841. doi:10.1001/jamanetworkopen.2026.3680
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。